An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma
- Resource Type
- Article
- Source
- In
Clinical Lymphoma, Myeloma and Leukemia August 2018 18(8):e327-e331 - Subject
- Language
- ISSN
- 2152-2650